Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Actinogen — Shareholder Meeting (November 2011)
32 slides from Actinogen Medical's shareholder meeting presentation, Nov 18, 2011
Slide 1: Actinogen Ltd Annual R&D Report 2010-2011
ACTI NOGEN Ltd ANNUAL R& D REPORT 2010-2011 For personal use only David Keast
Slide 2: Introduction
INTRODUCTION For personal use only Actinogen continues to concentrate on isolating new species of actinomycetes from the Western Australian environment
Slide 3: Staff & Functions
STAFF & FUNCTIONS For personal use only 2010-2011 Actinogen has enjoyed a very stable R&D staff profile over the year with: 3 Full time staff 3 Part time staff The Company continues its highly successful weekly brainstorm meetings, monthly, half yearly and annual reports. All reports go to the Board
Slide 4: Current R&D Projects
CURRENT R&D PROJECTS For personal use only Field sampling and isolation protocols remain stable After in house classification isolates are stored at subzero temps and move to dedicated R&D projects Antibiotic Plastic and Dereplication screening paper digestion Anti cancer screening Special Anti fung
Slide 5: Housekeeping
HOUSEKEEPING For personal use only The main function of this section still remains the isolation of new actinomycetes. The number of new isolates has been reduced this year to 1038 (representing some 6228 cultures). The Company now has some 20,000 isolates stored in two subzero “libraries” These rep
Slide 6: Housekeeping continued
Housekeeping continued For personal use only Some R&D projects are now maturing and as a result have required more dedicated staff time which led to the reduction in field sampling Other functions: [1] Maintenance of the Company’s electronic data base for the isolates and their properties [2]General
Slide 7: Antibiotic Screening
ANTIBIOTIC SCREENING For personal use only This approach has yielded from 6228 cultures: {1}: 4 active against the full panel of our MRSA screen {2}: 20 active against VRE Actinogen has refined its antibiotic screening tests to {3}: 6 active against now concentrate on very Pseudomonas aeruginosa act
Slide 8: Antibiotic Screening Continued: Clostridium difficile
ANTIBIOTIC SCREENING CONTINUED CLOSTRIDIUM DIFFICILE For personal use only Clostridium difficile is an anaerobic bacterium that is emerging as a serious and often lethal pathogen. It produces a fatal diarrhoea. Current treatment often involves severe and prolonged antibiotic treatment which also des
Slide 9: Antibiotic Screening Continued: Clostridium difficile
ANTIBIOTIC SCREENING CONTINUED CLOSTRIDIUM DIFFICILE For personal use only Actinogen has a panel of some 9 aerobic and anaerobic bacteria from normal gut flora against which it tests any antibiotics from its actinomycetes that have been shown to kill a series of C difficile that make up its screenin
Slide 10: Antibiotic Screening Continued
ANTIBIOTIC SCREENING CONTINUED Clostridium difficile For personal use only The antibiotics being produced are proceeding through dereplication tests, purification and will then be analysed for structures using Mass Spectrometry. Following these steps commercial interests will be investigated
Slide 11: Anti Cancer Screening In Vitro
ANTI CANCER SCREENING IN VITRO For personal use only Actinogen has developed this area as a major interest. Two initial screening protocols are used. [1] All actinomycetes producing antibiotics of interest are screened for toxicity against our panel of human and animal tumour cell lines. This checks
Slide 12: Anti Cancer Screening In Vitro
ANTI CANCER SCREENING IN VITRO For personal use only [2] Actinomycetes not producing antibiotics are also screened for potential anti tumour properties. The tests provide primary information on both cytotoxic and cytostatic properties of the actinomycete materials. This is very work intensive. 232 i
Slide 13: Anticancer Screening Continued
ANTICANCER SCREENING CONTINUED For personal use only Anti- angiogenesis factor screening 5 DAYS Actinogen has been developing a fertile egg assay system based on the inhibition of a known tumour angiogenesis factor by actinomycetes culture media. 10 DAYS
Slide 14: Anticancer Screening Continued
ANTICANCER SCREENING CONTINUED For personal use only A test run illustrating angiogenic activity Average percentages of chick vasculature formation following treatment with four cell lines 40 A549 35 B16 30 Vasculature (%) HeLa 25 L929 20 Control Day 5 15 Control day 7 10 Control Day 10 5 0 5 6 7 8
Slide 15: Plastic & Paper Digestion
PLASTIC & PAPER DIGESTION For personal use only Actinogen has a small series of actinomycetes that can digest brown paper and newspaper in as short a time as 3-4 weeks. Some of these can also colonise and grow on starch based plastic. Illustration of paper Currently the mechanisms behind digestion b
Slide 16: Plastic & Paper Digestion
PLASTIC & PAPER DIGESTION For personal use only Electron microscope studies indicate that the paper structure is broken down extensively while the isolates currently are shown only to colonise the plastic Paper structure Paper being digested
Slide 17: Plastic & Paper Digestion
PLASTIC & PAPER DIGESTION For personal use only CONTROL TEST CULTURES Actinogen has filed a Provisional Patent for methodologies in this area This is a rapidly developing interest to the Company
Slide 18: Anti Fungal Screening
ANTI FUNGAL SCREENING For personal use only Actinogen’s current interests in this area are : [1] clinically important yeasts( Candidas) [2] Brown rot disease of stonefruit [3] Pathogenic fungi of lawns
Slide 19: Anti Fungal Screening: Candidas
ANTI FUNGAL SCREENING Candidas For personal use only Fungal yeast infections caused by Candidas are widespread and caused by several species. Actinogen has a screening panel of 10 species. The reduced field sampling yielded 1038 isolates of which 151 proved positive for anti Candida activity at prim
Slide 20: Antifungal Screening: Brown rot
ANTFUNGAL SCREENING Brown rot For personal use only HISTORY [1] primary activity very strong but variable [2] Liquid cultures activity variable. Stability weak [3] HPLC dereplication nothing seen. LPLC nothing seen. Other libraries nothing seen [4] Final conclusion bioactive component volatile.Subse
Slide 21: Antifungal Screening: Pathogenic fungi for lawns
ANTIFUNGAL SCREENING Pathogenic fungi for lawns For personal use only Actinogen has a screening panel of four plant fungal pathogens. This is a new interest developed following the Currently 11 isolates are rapid increase in lawn active against all the fungal diseases due to screening panel. drought
Slide 22: Dereplication
DEREPLICATION For personal use only DAD1 A, Sig=204,4 Ref=off (7-10--10\7-10--10 2010-10-07 11-19-25\013-1401.D) mAU 6.070 mAU 80 40 70 60 30 50 20 2.579 40 7.835 7.236 4.283 30 10 20 0 10 250 300 350 400 450 500 550 nm 0 min 2 4 6 8 10 12 14 16 18 UV spectrum of a peak of HPLC chromatogram a known
Slide 23: Dereplication Continued
DEREPLICATION CONTINUED For personal use only The dereplication section services all other R&D projects as well as developing new technical approaches. This year collection techniques for individual chromatographic peaks have explored chromatograms for interesting activities and a new LPLC set up ha
Slide 24: Dereplication Continued
DEREPLICATION CONTINUED For personal use only Actinogen currently has some 236 isolates active against all MRSA in its screening panel 100 isolates active against its Candida panel 22 against its C difficile panel There are also a small number active against VRE and P. aeruginosa All of these isolat
Slide 25: Special Projects
SPECIAL PROJECTS For personal use only This area contains projects which have developed to detailed definition stages or are not able to be made public at this time [1] Anacardic acid [2] Brown paper, newspaper and glycerol digestion [3] Bioleaching of iron ores [4] Plant growth hormones
Slide 26: Special Projects: Anacardic Acid
SPECIAL PROJECTS CONTINUED For personal use only [1] ANACARDIC ACID Preliminary Mass Spectrometry indicates that the anacardic acid being produced by Actonogen’s actinomycete is structurally similar to that commercially available A LPLC method is being finalised for the purification of the anacardic
Slide 27: Special Projects: Paper and Glycerol Digestion
SPECIAL PROJECTS CONTINUED For personal use only [2] PAPER and GLYCEROL DIGESTION This project is now well advanced . It has recently undergone independent assessment. Actinogen’s results have been verified. Enzymes being produced are used in the biofuel industry. Experimental production costs are b
Slide 28: Special Projects: Bioleaching of Iron Ore
SPECIAL PROJECTS CONTINUED For personal use only [3] BIOLEACHING OF IRON ORE Mass Sectrometry has confirmed that the siderophore produced by one of Actinogen’s actinomycete’s is enterobactin previously only reported in other bacteria. Enterobactin Trials in progress on column leaching potential of i
Slide 29: Special Projects: Plant Growth Hormones
SPECIAL PROJECTS CONTINUED For personal use only [4] PLANT GROWTH HORMONES TOTAL BEAN WEIGHT {GMS @ D45} 70 60 50 40 GMS 30 20 10 0 WET WEIGHT WATER MEDIUM 1503 1487
Slide 30: Special Projects Continued
SPECIAL PROJECTS CONTINUED For personal use only WATER MEDIUM 1503 1487 WATER MEDIUM 1503 1487
Slide 31: Proving the company
Proving the company For personal use only It is crucial that Actinogen proves itself for both the scientific community and commercial interests. This has to be through the publishing of results via peer reviewed journals and/or by obtaining independent corroboration of results by independent assesso
Slide 32: Summary
SUMMARY For personal use only I hope that I have conveyed to you that Actinogen has a very active R&D programme in place. This past year has seen the development of detail in some of the more promising projects with results being prepared for publication and to go forward in search of commercial int